CSL

CSL Behring and GKV-Spitzenverband Agree on Reimbursement Price for HEMGENIX® – Europe’s First Gene Therapy for Haemophilia B

2 April 2025 -- Marburg, Germany -- CSL Behring and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) have successfully concluded negotiations on the reimbursement price of HEMGENIX. This agreement marks the availability of the first gene therapy approved in Europe for haemophilia B under an innovative, national, success-based reimbursement model, being implemented for...

First patients treated with HEMGENIX® (etranacogene dezaparvovec) gene therapy for haemophilia B in Denmark

21 January 2025 – Copenhagen, Denmark – CSL Behring Denmark today announced that the first Danish patients with haemophilia B were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec). HEMGENIX® is the first one-time gene therapy to be approved in Europe for the treatment of adults with severe and moderately severe haemophilia B, an inherited...

CSL Behring Announces First Two Patients Treated with HEMGENIX (etranacogene dezaparvovec) Gene Therapy for Haemophilia B in Europe

4 July 2024, Marburg, Germany– Global biotechnology leader CSL Behring (ASX: CSL) today announced that two haemophilia B patients were treated with the gene therapy HEMGENIX (etranacogene dezaparvovec) at Haemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX the first gene therapy administered as a treatment in a real-world setting for haemophilia B in...
CSL Global Headquarters, 655 Elizabeth Street, Melbourne VIC 3000 Australia

+61 3 9389 1911